Results 91 to 100 of about 27,000,079 (254)

Type I interferon pathway genetic variants in severe COVID-19

open access: yesVirus Research
Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2. According to the World Health Organization (WHO), there have been over 760 million reported cases and over 6 million deaths caused by this disease worldwide.
A.F.L. Montenegro   +2 more
doaj   +1 more source

Innate sensing of HIV-infected cells [PDF]

open access: yes, 2011
Cell-free HIV-1 virions are poor stimulators of type I interferon (IFN) production. We examined here how HIV-infected cells are recognized by plasmacytoid dendritic cells (pDCs) and by other cells.
Richard E. Randall   +31 more
core   +2 more sources

“Low‐Positive” MOG‐IgG Cases Among Adults With a First Event Suggestive of Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine the prevalence and clinical characteristics of patients with “low‐positive” (LP) MOG‐IgG (titres 1:160–1:320) among adults with a first demyelinating event (FDE) suggestive of multiple sclerosis (MS). Methods From the Barcelona CIS inception cohort, we included adult patients with serum collected ≤ 6 months from the FDE.
Javier Villacieros‐Álvarez   +29 more
wiley   +1 more source

Herpes simplex virus triggers and then disarms a host antiviral response [PDF]

open access: yes, 2001
Virus infection induces an antiviral response that is predominantly associated with the synthesis and secretion of soluble interferon. Here, we report that herpes simplex virus type 1 virions induce an interferon-independent antiviral state in human ...
Smiley, J R   +5 more
core   +1 more source

Autoimmune Comorbidities as Modifiers of Phenotypic Heterogeneity in Facioscapulohumeral Dystrophy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Facioscapulohumeral dystrophy type 1 (FSHD1) shows clinical heterogeneity that is only partly explained by D4Z4 repeat unit (RU) size. Although immune and inflammatory mechanisms may contribute to disease variability, the prevalence and clinical impact of autoimmune diseases in FSHD remain unclear.
Jonathan Pini   +9 more
wiley   +1 more source

STING-Mediated IFI16 Degradation Negatively Controls Type I Interferon Production

open access: yesCell Reports, 2019
Summary: γ-interferon-inducible protein-16 (IFI16), a key DNA sensor, triggers downstream STING-dependent type I interferon (IFN-I) production and antiviral immunity.
Dapei Li   +12 more
doaj   +1 more source

Mapuera virus, a rubulavirus that inhibits interferon signalling in a wide variety of mammalian cells without degrading STATs [PDF]

open access: yes, 2007
Majouera virus (MPRV) is a paramyxovirus that was originally isolated from bats, but its host range remains unknown. It was classified as a member of the genus Rubulavirus on the basis of structural and genetic features.
Goodbourn, S   +8 more
core   +1 more source

Artificial Intelligence in Systemic Sclerosis: Clinical Applications, Challenges, and Future Directions

open access: yesArthritis Care &Research, EarlyView.
Systemic sclerosis (SSc) is a rare autoimmune disease defined by immune dysregulation, vasculopathy, and progressive fibrosis of the skin and internal organs. Despite advances in care, major complications such as interstitial lung disease (ILD) and myocardial involvement remain the leading causes of morbidity and mortality.
Cristiana Sieiro Santos   +2 more
wiley   +1 more source

Evidence for increased interferon type I activity in CD8+ T cells in giant cell arteritis patients. [PDF]

open access: yesFront Immunol, 2023
van Nieuwland M   +8 more
europepmc   +1 more source

Interferon signaling in viral hepatitis [PDF]

open access: yes, 2013
Hepatitis C virus (HCV) is a single stranded positive RNA virus classified in 6 different genotypes. Hepatocytes are the main targets of HCV infection. It has been estimated that 60 to 70% of the infected patients develop chronic infection.
Trincucci, Gaia
core   +1 more source

Home - About - Disclaimer - Privacy